GlassScriptPhysician profile
Emme Eleyna Deamont
NPI 1902667132
$802.16
in general payments reported to CMS, 2019-2025
15 companies · $373 in 2025
The $373 reported for 2025 was more than what 80% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $429 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $144.64 | 2024-2025 | |
| Organon LLC | $124.38 | 2024 | |
| Hologic Sales and Service, LLC | $110.87 | 2024-2025 | Myosure Tissue Removal Device, Novasure, Acessa Provu System |
| Exeltis, USA INC. | $91.23 | 2024 | Slynd |
| Millicent US INC | $63.35 | 2025 | Intrarosa, Femlyv |
| Biogen, INC. | $42.85 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $38.32 | 2024 | Paragard T 380a |
| Shield Therapeutics INC | $35.50 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.13 | 2025 | |
| Mayne Pharma Commercial LLC | $25.52 | 2025 | |
| Pfizer INC. | $23.30 | 2024 | |
| Novo Nordisk INC | $21.22 | 2025 | Wegovy |
| Astellas Pharma US INC | $18.84 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $17.92 | 2024 | Gardasil 9, Gardasil |
| Sumitomo Pharma America, INC. | $17.09 | 2024 | Myfembree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emme Deamont listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.